Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: The HORIZON pivotal fracture trial.

被引：0
|
作者：
Black, D. M.
Boonen, S.
Cauley, J.
Delmas, P.
Eastell, R.
Reid, I.
Rosario-Jansen, T.
Caminis, J.
Zhang, J.
Hu, H.
Cummings, S.
机构：
[1] UCSF, San Francisco, CA USA
[2] Leuven Univ, Louvain, Belgium
[3] Univ Pittsburgh, Pittsburgh, PA USA
[4] Univ Lyon 1, F-69365 Lyon, France
[5] Univ Sheffield, Sheffield, S Yorkshire, England
[6] Univ Auckland, Auckland 1, New Zealand
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] UCSF, San Francisco, CA USA
[9] CPMC Res Inst, San Francisco, CA USA
来源：
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [31] Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
    Grbic, John T.
    Landesberg, Regina
    Lin, Shou-Qing
    Mesenbrink, Peter
    Reid, Ian R.
    Leung, Ping-Chung
    Casas, Noemi
    Recknor, Christopher P.
    Hua, Ye
    Delmas, Pierre D.
    Eriksen, Erik F.
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2008, 139 (01): : 32 - 40
  • [32] EFFECT OFA ONCE-YEARLY ZOLEDRONIC ACID ON BMD AND THE RISK OF FALLING IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Lin, H.
    Xu, T.
    Fan, L.
    Yang, H.
    Chen, X.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S649 - S650
  • [33] BONE MINERAL DENSITY AFTER HIP FRACTURE: VARIATIONS IN RESPONSE TO ONCE-YEARLY IV ZOLEDRONIC ACID 5 MG
    Magaziner, Jay
    Orwig, Denise
    Lyles, Kenneth W.
    Nordsletten, Lars
    Boonen, Steven
    Adachi, Jonathan
    Colon-Emeric, Cathleen
    Bucci-Rechtweg, Christina
    Mesenbrink, Peter
    Pieper, Carl
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S213 - S213
  • [34] Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial
    Yang, L.
    Sycheva, A. V.
    Black, D. M.
    Eastell, R.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 329 - 338
  • [35] Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial
    L. Yang
    A. V. Sycheva
    D. M. Black
    R. Eastell
    Osteoporosis International, 2013, 24 : 329 - 338
  • [36] Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis
    Delmas, Pierre D.
    Munoz, Francoise
    Black, Dennis M.
    Cosman, Felicia
    Boonen, Steven
    Watts, Nelson B.
    Kendler, David
    Eriksen, Erik F.
    Mesenbrink, Peter G.
    Eastell, Richard
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (09) : 1544 - 1551
  • [37] Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery
    Kashii, Masafumi
    Kamatani, Takashi
    Abe, Shingo
    Yoshida, Ayanori
    Yamamoto, Kengo
    Koizumi, Kota
    Mizuno, Naoko
    Kuriyama, Kohji
    Yoshikawa, Hideki
    BONE, 2022, 155
  • [38] Effect of once-yearly infusion of zoledronic acid 5 mg on biochemical markers of bone turnover: Data from horizon-PFT
    Delmas, P. D.
    Bauer, D.
    Black, D.
    Boonen, S. R.
    Cosman, F.
    Eastell, R.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S29 - S29
  • [39] Effect of once-yearly infusion of zoledronic acid 5 mg on biochemical markers of bone turnover: data from HORIZON-PFT
    Delmas, P. D.
    Bauer, D.
    Black, D.
    Boonen, S.
    Cosman, F.
    Eastell, R.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S130 - S131
  • [40] Effect of once-yearly infusion of zoledronic acid 5 mg on biochemical markers of bone turnover: Data from horizon-pft
    Delmas, P.
    Bauer, D.
    Black, D.
    Boonen, S.
    Cosman, F.
    Eriksen, E. F.
    Mesenbrink, R.
    Eastell, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 523 - 523
12345